SpaceX vs. Rocket Lab: How Do They Compare as Investments?

SpaceX is targeting a $1.77 trillion IPO valuation, versus Rocket Lab's roughly $66 billion market cap, highlighting a stark valuation gap despite both companies still being unprofitable. SpaceX generated $18.7 billion of 2025 revenue and $4.4 billion of operating income from Starlink, but its AI segment lost $6.4 billion in 2025; Rocket Lab posted $602 million of revenue and negative $321.8 million in free cash flow, with Neutron's debut still delayed. The article argues Rocket Lab's valuation is easier to defend than SpaceX's, but both names face significant execution risk and rich price-to-sales multiples.

Analysis

The market is collapsing two very different businesses into the same “space” bucket, but the real second-order effect is a valuation-compression test for every pre-profitability hardware/software hybrid. If a listed pure-play like RKLB can sustain a high-double-digit revenue multiple while still funding an expensive launch roadmap, then public comparables for other frontier-tech names can stay detached from near-term earnings longer than skeptics expect. The harder question is not whether SpaceX is bigger — it’s whether its IPO creates a new reference point that drags private-market marks for adjacent venture-backed space and defense suppliers higher, even if public-market investors remain unwilling to underwrite the same premium.

The key catalyst for RKLB is not “more space demand,” but proof that Neutron converts it from a niche launch/components story into a credible scale platform. That matters because the re-rating, if it comes, is path-dependent: one clean launch likely helps sentiment, but a sustained move in the stock requires evidence of cadence, gross-margin expansion, and capex discipline over multiple quarters. Conversely, any additional delay likely hits the stock disproportionately because the market is already paying for an execution win that has not yet been delivered.

SpaceX’s risk is governance-plus-capital-allocation, not product-market fit. The IPO can still work as a near-term sentiment event, but the second-order issue is whether investors start valuing the company on the economics of its profitable core while mentally discounting the loss-making AI bet; if that separation fails, dilution of the “best asset” premium becomes a real overhang. That creates a useful contrarian setup: the market may be overestimating how much of SpaceX’s headline valuation is transferable to the public comps, while underestimating how quickly RKLB can rerate if Neutron merely proves viable rather than dominant.

Key Decisions for Investors

• Maintain a tactical long RKLB position only into Neutron launch windows; use a 3-6 month horizon and size for binary execution risk. Best risk/reward is on a successful first-flight or credible launch-date confirmation, not on the IPO itself.
• Prefer a pair trade: long RKLB / short NDAQ- or broad-growth-beta only if you want exposure to speculative re-rating; otherwise avoid chasing RKLB outright above current multiples because any Neutron slip can trigger a 20-30% drawdown.
• Avoid shorting SpaceX through public proxies immediately into IPO pricing. If anything, use the IPO as a catalyst to short overextended private-market enthusiasm in adjacent unprofitable aerospace suppliers after the initial pop has faded.
• For option exposure, consider RKLB call spreads into the first Neutron attempt with defined downside; the trade works if the market starts discounting a 12-18 month path to scale, but should be exited if launch slips beyond the next quarter.
• If SpaceX lists near the top of range and trades well, look for a medium-term short against crowded venture-style names in the broader AI/space theme, since the IPO may prove that investors are willing to pay for narrative—but only for the market leader.